Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Developmental therapeutics

5084 - Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine (gem) in patients (pts) with refractory solid tumors

Date

09 Sep 2017

Session

Developmental therapeutics

Presenters

Antoine Italiano

Citation

Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367

Authors

A. Italiano1, J.R. Infante2, G. Shapiro3, K.N. Moore4, P. Lorusso5, S. Postel-Vinay6, S. Cousin7, M. Toulmonde7, C. Lucchesi7, E. Blackwood8, S. Mahrus8, X. Lu8, M. Tagen8, J. Schutzman8, J. Lauchle8, J. Soria9

Author affiliations

  • 1 Medicine, Institute Bergonié, 33076 - Bordeaux/FR
  • 2 Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, 37203 - Nashville/US
  • 3 Early Drug Development Center, Dana-Farber Cancer Institute, 02215 - Boston/US
  • 4 Department Of Obstetrics And Gynecology, University of Oklahoma Health Sciences Center, 73117 - Oklahoma City/US
  • 5 Yale Cancer Center, Yale University, New Haven/US
  • 6 Départemement D’innovation Thérapeutique Et Des Essais Précoces (ditep), Institut Gustave Roussy, 94800 - Villejuif/FR
  • 7 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 8 Early Clinical Development, Genentech Inc, 94081 - South San Francisco/US
  • 9 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
More

Resources

Abstract 5084

Background

Checkpoint kinase 1 (Chk1) inhibition following chemotherapy overrides cell cycle arrest and induces mitotic catastrophe and cell death. GDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor that results in tumor shrinkage and growth delay in xenograft models.

Methods

This Phase I trial enrolled pts with refractory solid tumors and ECOG 0-1 status. Patients received IV gem 1000 mg/m2 followed ∼24 hours later by GDC-0575 (15-60 mg) PO, or IV gem 500 mg/m2 followed ∼24 hours later by GDC-0575 (45-105 mg) PO, weekly for 2 of 3-week cycles. TP53 was evaluated in archival tumor tissue by gene sequencing. Safety, pharmacokinetics (PK), pharmacodynamics, and tumor response by RECIST v1.1 were investigated.

Results

Of 81 pts treated, 73% were female, the median age was 56 years (range 27-75), and 48% were ECOG PS 0. The most common tumor types were breast (46%), and soft tissue sarcoma and NSCLC (both 7%). Dose escalation was halted at GDC-0575 60 mg and 105 mg with gem 1000 mg/m2 and gem 500 mg/m2, respectively, as pts experienced Grade 4 thrombocytopenia and Grade 3-4 febrile neutropenia as dose-limiting toxicities. The most frequent adverse events (all grades) related to GDC-0575 and/or gem were neutropenia (80%), anemia (56%), fatigue (47%), nausea (46%), and thrombocytopenia (40%). Maximum concentrations of GDC-0575 were achieved within 2 hours of dosing, and its half-life was ∼23 hours. No PK drug-drug interaction was observed between GDC-0575 and gem. Among pts treated with GDC-0575 and gem 500 mg/m2, there were 4 cPRs (2x sarcoma, NSCLC, TNBC) and 3 SDs (TNBC, NSCLC, SCLC) for ≥ 6 months. Exome sequencing data from tumor samples obtained at progression did not reveal mutations in Chk1 but identified mutations in genes known to regulate apoptosis.

Conclusions

The Chk1 inhibitor GDC-0575 can be safely combined with a standard or modified dose and schedule of gem. Hematological toxicities were frequent but manageable. Preliminary anti-tumor activity was observed in patients with a variety of refractory solid tumors treated with GDC-0575 in combination with gem 500 mg/m2.

Clinical trial identification

NCT01564251

Legal entity responsible for the study

Genentech, Inc.

Funding

Genentech, Inc.

Disclosure

G. Shapiro: Advisory boards for Pfizer, Lilly, G1 Therapeutics, Roche and Vertex Pharmaceuticals. Research funding from Pfizer and Lilly. K.N. Moore: Advisory boards for Advaxis, AstraZeneca, Clovis, Immunogen, Genentech/Roche, Tesaro and VBL therapeutics. P. Lorusso: AstraZeneca, Roche Genentech, AbbVie, Bayer, Boerhinger Ingelheim, Alexion, Omniox. E. Blackwood, S. Mahrus, X. Lu, M. Tagen, J. Schutzman, J. Lauchle: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd. J-C. Soria: Consultancy fees from AstraZeneca, Astex, Covagen, Clovis, GSK, Gammamabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, Pierre Fabre, Roche-Genentech, Sanofi, Servier, Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.